A meta-analysis on the immunogenicity of prototype, monovalent-adapted and bivalent vaccines against SARS-CoV-2 wildtype, Omicron BA.1 and Omicron BA.4/5 in healthy adults

• Published in: Virology (New York, N.Y.) Vol. 606; p. 110509
• Main Authors: Banga Ndzouboukou, Jo-Lewis, Kamara, Abdul A., Ullah, Nadeem, Lei, Qing, Fan, Xiong-lin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2025
• Subjects: Adult; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; Bivalent vaccine; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 - virology; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Healthy Volunteers; Humans; Immunization, Secondary; Immunogenicity; Immunogenicity, Vaccine; Infectious Disease; Monovalent-adapted vaccine; Neutralizing antibody; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; SARS-CoV-2 variants; Second booster; Monovalent-adapted vaccine; Second booster; SARS-CoV-2 variants; Bivalent vaccine; Immunogenicity; Neutralizing antibody

Although COVID-19 is no longer classified as the first public health emergency, nevertheless, it still presents a serious menace to the health of the global population. Consequently, the development of COVID-19 vaccines possessing an optimal composition that can elicit broad-spectrum neutralizing re...